Published 19 May 2025· via azure.microsoft.com· Blog post
Global Innovators Accelerate Scientific Discovery with AI-Driven Agents
GSK, The Estée Lauder Companies · Pharma · United States
↓ 200 h
time
As reported by the source; not independently verified.
Summary
Microsoft Discovery is a new enterprise AI agent platform designed to transform research and development (R&D) across sectors. By orchestrating specialized AI agents with a sophisticated graph-based knowledge engine, researchers and scientists can reason contextually through complex data, simulate experiments, and iterate research plans faster than ever before. Built on Azure High Performance Computing (HPC) and Azure AI Foundry, it emphasizes trust, compliance, and extensibility. Real-world impact is demonstrated by Microsoft researchers rapidly developing a sustainable immersion datacenter coolant, a process that normally takes years, in just 200 hours. GSK aims to accelerate medicinal chemistry, while The Estée Lauder Companies focuses on faster product innovation. The platform integrates partner technology from NVIDIA, Synopsys, and PhysicsX to enable advances in pharma, materials, semiconductor design, and industrial engineering. Strategic alliances with Accenture and Capgemini are helping scale deployments. Microsoft Discovery is positioned as a future-proof system for solving the most challenging R&D problems using AI agents and Microsoft’s secure cloud foundation.
The problem
- 01R&D processes in science and engineering are slow, complex, and highly iterative.
- 02Scientific knowledge is distributed, nuanced, and siloed across domains.
- 03Simulating and validating new materials (such as sustainable datacenter coolants) can take years with traditional methods.
- 04Connecting data, tools, and knowledge across domains is difficult for research teams lacking deep computational expertise.
- 05Compliance and trust in AI systems is required for enterprise-scale adoption.
What they built
- 01Microsoft Discovery orchestrates domain-specialized AI agents (e.g., for simulation, literature review) using a graph-based knowledge engine.
- 02Built on Azure HPC, Azure AI Foundry, and Microsoft Copilot for trusted and compliant infrastructure.
- 03Researchers can build and define custom agents to fit specific R&D workflows.
- 04Partnerships extend the platform with NVIDIA (AI/GPUs), Synopsys (semiconductor design), and PhysicsX (physics models).
- 05Consulting partners Accenture and Capgemini scale adoption and co-innovation.
Reported results
- 01Reduced the time to discover a sustainable, non-PFAS datacenter coolant from years to about 200 hours (plus under 4 months for lab prototype synthesis).
- 02Enabled faster development cycles at GSK for medicinal chemistry and at The Estée Lauder Companies for product innovation.
- 03Brings capabilities for rapid parallel prediction, testing, and workflow automation to R&D teams.
- 04Accelerates semiconductor and material science breakthroughs through third-party integrations.
- Orchestrated domain-specialized AI agents for R&D
- Trusted, compliant AI infrastructure for enterprise adoption
- Accelerated research and iteration cycles
- Extended platform through strategic partner integrations
Source
azure.microsoft.com
Blog post · 19 May 2025 · Published by a vendor
How this deployment compares
Computed from the library · data 10 Nov 2026This is the only GSK deployment in the library. It is one of 12 life sciences innovation deployments, 9 of them in Pharma.
GSK in the library
The only GSK deployment in the library
GSK is also named in 1 multi-company roundup.
Followed upA newer GSK record from 2026 is in the library, so the AI program continued after this announcement.
Same pattern, whole library
One of 12 life sciences innovation deployments
- Pharma accounts for 9 of them (75%), more than any other industry.
- 5 records of this pattern came before it; 5 have been published since.
- Only 2 of the 12 put a number on the result (17%).
- Distinctive claim: Ecosystem & partnerships outcomes are reported by only 1 peers (8%).
- Microsoft67%
- AWS25%
- GCP8%
- Azure AI 4
- Azure OpenAI 3
- Azure HPC 2
- Copilot 2
- Azure 2
- AI 2
Outlined: used in this record.
Shares describe this library, not the whole market.
Results against peers
What peers report
- Time & speed283 figures, all industries · middle half 30%–76%50%median reduction
- Risk, reliability & safety13 figures, all industries · middle half 60%–90%70%median reduction
Peer figures are as reported by their sources; percentage claims only.
How we checked this record
Evidence tier: supported
A credible source with a named customer, but not the organization's own account.
- Named organization
- GSK, The Estée Lauder Companies
- Who published the source
- The technology vendor
- Deployment status
- The source does not say
- Quantified result
- The source reports at least one figure
- Source link
- Online at last check
Last re-checked 13 Jun 2026.
This record is evidence for
Same pattern, other organizations
All life sciences innovation deployments- 27 May 2026PharmaUnited States
PozeSCAF Discovery Solutions — Amazon Bedrock + high-performance simulation on AWS to accelerate drug discovery
PozeSCAF Discovery Solutions · Life sciences innovation · AWS
PozeSCAF Discovery Solutions (formerly Immunocure Discovery Solutions) turned to AWS for scalable, high-performance infrastructure to optimize molecular dynamics workloads. The company cut simulation runtimes by more than half, reduced compute costs, and accelerated its drug discovery pipeline. It also began exploring generative AI/agentic workflows with Amazon Bedrock to build knowledge graphs from project data and flag potential side effects earlier.
AgenticExploring
2.5×simulation throughput increase - 27 May 2026PharmaUnited Kingdom
Sonrai Accelerates Single-Cell RNA-seq Data Analysis Using Amazon Bedrock
Sonrai · Life sciences innovation · AWS
Researchers in the biotech and pharmaceutical industries grapple daily with the complexity and volume of single-cell RNA sequencing (scRNA-seq) datasets, which are crucial for understanding diseases and developing targeted therapies. Sonrai sought to use generative AI to simplify and streamline interpretation of scRNA-seq data and reduce the manual burden on immunologists. Sonrai Discovery uses large language models through Amazon Bedrock to automate cluster annotation, generate consistent text reports, and support faster analysis on AWS.
↓ 5×error reduction - 29 Apr 2026HealthcareUnited States
Genentech leverages generative AI with Amazon Bedrock Agents to accelerate drug discovery
Genentech · Life sciences innovation · AWS
Genentech uses Amazon Bedrock Agents with Anthropic Claude Sonnet 3.5 to automate complex biomedical research workflows for biomarker validation. The gRED Research Agent processes and synthesizes information from millions of scientific data sources using multi-agent collaboration and Retrieval Augmented Generation (RAG). This automation reduces manual research time from weeks to minutes, freeing scientists to focus on high-impact tasks and accelerating drug discovery.
>43 htime - 3 Mar 2026PharmaCanada
BenchSci decodes disease biology with Neo4j and Google Cloud to accelerate drug discovery
BenchSci · Life sciences innovation · GCP
BenchSci transforms fragmented biomedical evidence into a graph-native model of disease biology, empowering 9 of the top 10 pharmaceutical companies to de-risk and accelerate discovery. BenchSci’s ASCEND platform combines large language models with the Biological Evidence Knowledge Graph (BEKG), an experimentally grounded knowledge system that integrates open-access literature, closed-access publications, and proprietary pharmaceutical datasets. Its LENS extraction engine uses Google Cloud Vertex AI and Gemini models to interpret scientific papers with contextual awareness and validate claims against associated imagery before materializing structured assertions into Neo4j.
Production